Stay updated on CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma
Sign up to get notified when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.

Latest updates to the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe history page now shows Revision: v3.3.2 and no longer lists Revision: v3.2.0.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded a new 'Study Status' section to the record history (2025-11-12) and removed the government-funding notice (2025-08-12).SummaryDifference0.7%

- Check41 days agoChange DetectedThe new screenshot shows the same version history and study details as the old one, with no substantive content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedUpdated page now communicates current operating status and potential processing delays due to funding, notes NIH Clinical Center is open, and increments the version to v3.2.0.SummaryDifference10%

- Check70 days agoChange DetectedVersion update from v3.0.2 (deletion) to v3.1.0 (addition); signals new release with potential updates or features. If there are no explicit feature details, the change is primarily a release/version increment.SummaryDifference0.2%

- Check84 days agoChange DetectedRevision bumped from v3.0.1 to v3.0.2; 'Back to Top' was removed. No changes to pricing, stock, or names.SummaryDifference0.6%

Stay in the know with updates to CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma
Enter your email address, and we'll notify you when there's something new on the CAMMA 2 Clinical Trial - Cevostamab in BCMA-Exposed Myeloma page.